US20260234286
2026-08-13
Chemistry; metallurgy
C07K16/3092
The invention focuses on the development of antibodies targeting Mucin 16 (MUC16), a glycoprotein highly expressed in ovarian cancer. It introduces novel full-length human IgG antibodies that specifically bind to MUC16. Additionally, it presents bispecific antibodies that target both MUC16 and CD3, which is essential for T cell activation. These bispecific antibodies can activate T cells in the presence of MUC16-expressing tumors, aiming to enhance immune response against such cancer cells.
The invention includes anti-MUC16 antibody-drug conjugates designed to inhibit tumor growth in vivo. Furthermore, the bispecific antigen-binding molecules can simultaneously bind to MUC16 and CD3, facilitating T cell-mediated destruction of cancer cells. This dual binding capability is particularly beneficial for treating cancers where an enhanced immune response against MUC16 is advantageous, such as ovarian cancer.
These antibodies and bispecific molecules are applicable in therapeutic contexts where targeting MUC16-expressing cells is desired. They offer potential treatments for various cancers by directing T cell activity to tumor cells. Additionally, the anti-MUC16 antibodies can be employed in diagnostic methods to detect MUC16 presence in tissue or plasma samples, aiding in cancer diagnosis and monitoring.
The invention provides detailed sequences of heavy and light chain variable regions (HCVRs and LCVRs) of exemplary anti-MUC16 antibodies. These sequences are critical for the specificity and efficacy of the antibodies. The bispecific antibodies utilize a combination of these sequences to achieve their dual targeting function, enhancing their therapeutic potential against MUC16-expressing tumors.
The invention builds upon previous applications and patents, incorporating advanced sequence listings and methodologies for identifying complementarity-determining regions (CDRs) within antibody sequences. These CDRs are crucial for antigen binding and are identified using established conventions like the Kabat and Chothia definitions. Such detailed molecular insights ensure the antibodies' precision in targeting MUC16, paving the way for effective cancer therapies.